ICAN I/O – Data sciences

MAESTRIA: Machine Learning Artificial Intelligence Early Detection Stroke Atrial Fibrillation

• Consortium of 18 partners from Europe, the United States and Canada responding to an H2020 call for projects on digital diagnostics.
• A highly innovative project to improve the detection of atrial cardiomyopathy, which is responsible for the onset of atrial fibrillation and embolic vascular accidents, using machine learning and AI (Artificial Intelligence).
• The ICAN I/O Data Science team plays a central role in integrating multimodal data (imaging, clinical, omics) to improve diagnostic accuracy and identify new therapeutic targets, thereby increasing the effectiveness of treatment and preventing complications.
• The ICAN I/O team is also leading the development of the MAESTRIA demonstrator, an innovative digital platform designed to guide atrial fibrillation risk assessment and management, improve diagnosis and support treatment decisions through a scalable, user-centric approach.

ARTEMIs : AcceleRating the Translation of virtual twins towards a pErsonalised Management of fatty lIver patients

• The ARTEMIs project is developing ‘virtual twins’ using computer models and machine learning, integrated into a Clinical Decision Support System ( CDSS) for the management of metabolic fatty liver disease (MFLD) .
• Targeting a disease that affects 25% of the population, ARTEMIs also focuses on early intervention for the cardiovascular complications associated with FAD.
• The system aims to personalise treatment by predicting the course of the disease, assessing the effectiveness of treatments and encouraging a healthier lifestyle.
• The project concludes with a proof-of-concept study to assess the effectiveness of this integrated approach in a clinical setting.

MEDITWIN: using digital twins to develop tomorrow’s personalised medicine

• Consortium comprising 7 University Hospital Institutes (IHUs) , including ICAN, Nantes University Hospital, Inria, associated start-ups and Dassault Systèmes
• Project France 2030 announced on Monday 11 December 2023 in the presence of French President Emmanuel Macron.
• Using personalised virtual twins of organs, metabolism and cancerous tumours
• 5 years, from 2024 to 2029
• Aims: provide a diagnosis of the risk of cardiovascular disease for high-risk patients andhelp specialist doctorschoose treatments for effective patient follow-up

RESIST-PP: the link between diet, innate immunity and the risk of infection

• An EU-funded project to explore how high-fat diets induce postprandial inflammation and atherogenic dyslipidaemia via metabolic endotoxaemia influenced by gut microbiota.
• The project aims to study the impact of bacteria-derived metabolites on the susceptibility of obese and diabetic patients to infections, to analyse the interactions between immune cells and the blood microbiota, and to carry out studies on mouse models.
• The ICAN I/O platform is participating in this project by integrating multimodal data, improving our understanding of the risks of diet-induced infection and developing new treatment and prevention strategies for metabolic and infectious diseases.

Multimodal integration

• The ICAN I/O platform specialises in multimodal integration and is actively involved in a number of national and European projects focusing on omics studies, working closely with the ICAN Omics Lipidomics and ICAN Omics Metabolomics platforms .
• ICAN I/O uses a range of analyses from classical statistical analysis to advanced machine learning algorithms to achieve study objectives.
• The ICAN I/O team is continually developing custom visualisation tools to improve the presentation and interpretation of results.
• The platform’s solid experience is backed up by several major scientific publications that demonstrate its expertise.

Omics